First clinical trial with etomoxir in patients with chronic congestive heart failure.

No abstract is available for this paper.

• Publication year

  2000

• Venue

  Clinical science

• Publication date

  2000-07-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1042/CS0990027PMID 10887055
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Sarcoplasmic reticulum Ca(2+)-ATPase overexpression by adenovirus mediated gene transfer and in transgenic mice.

  1998cited by this paper
• Congestive heart failure: role of cross-bridge cycle kinetics.

  1998cited by this paper
• Sarcoplasmic reticulum Ca2+-ATPase overexpression by adenovirus mediated gene transfer and in transgenic mice

  1998cited by this paper
• Alterations of cross-bridge kinetics in human atrial and ventricular myocardium.

  1998cited by this paper
• Changes in gene expression in the intact human heart. Downregulation of alpha-myosin heavy chain in hypertrophied, failing ventricular myocardium.

  1997cited by this paper
• Myosin heavy chain gene expression in human heart failure.

  1997cited by this paper
• Etomoxir improves left ventricular performance of pressure-overloaded rat heart.

  1997cited by this paper
• Inhibition of carnitine palmitoyltransferase-1 in rat heart and liver by perhexiline and amiodarone.

  1996cited by this paper
• Modification of sarcoplasmic reticulum gene expression in pressure overload cardiac hypertrophy by etomoxir

  1996cited by this paper
• A preliminary study of growth hormone in the treatment of dilated cardiomyopathy.

  1996cited by this paper
• Existence of the Frank-Starling mechanism in the failing human heart. Investigations on the organ, tissue, and sarcomere levels.

  1996cited by this paper
• Roles of natriuretic peptides in heart failure.

  1996cited by this paper
• Award-winning and Finalist Abstracts from the 69th Scientific Sessions of the American Heart Association New Orleans, LA, USA November 10–13, 1996

  1996cited by this paper
• Differential influences of carnitine palmitoyltransferase-1 inhibition and hyperthyroidism on cardiac growth and sarcoplasmic reticulum phosphorylation.

  1995cited by this paper
• Positive and negative inotropic effects of DL-sotalol and D-sotalol in failing and nonfailing human myocardium under physiological experimental conditions.

  1995cited by this paper
• Dietary medium-chain triglycerides can prevent changes in myosin and SR due to CPT-1 inhibition by etomoxir.

  1995cited by this paper
• Alterations in intracellular calcium handling associated with the inverse force-frequency relation in human dilated cardiomyopathy.

  1995cited by this paper
• Rapid ventricular induction of brain natriuretic peptide gene expression in experimental acute myocardial infarction.

  1995cited by this paper
• CPT-1 inhibition by etomoxir has a chamber-related action on cardiac sarcoplasmic reticulum and isomyosins.

  1994cited by this paper
• Relation between myocardial function and expression of sarcoplasmic reticulum Ca(2+)-ATPase in failing and nonfailing human myocardium.

  1994cited by this paper
• Modification of myosin isozymes and SR Ca2+-pump ATPase of the diabetic rat heart by lipid-lowering interventions

  1994cited by this paper
• Sarcoplasmic reticulum gene expression in cardiac hypertrophy and heart failure.

  1994cited by this paper
• Angiotensin I and II exert inotropic effects in atrial but not in ventricular human myocardium. An in vitro study under physiological experimental conditions.

  1993cited by this paper
• Increased Plasma Levels of Brain Natriuretic Peptide in Patients With Acute Myocardial Infarction

  1993cited by this paper
• Molecular phenotype of the hypertrophied and failing myocardium

  1993cited by this paper
• Selective changes in cardiac gene expression during compensated hypertrophy and the transition to cardiac decompensation in rats with chronic aortic banding.

  1993cited by this paper
• Alterations of the force-frequency relationship in the failing human heart depend on the underlying cardiac disease.

  1992cited by this paper
• Contractile proteins and sarcoplasmic reticulum calcium-ATPase gene expression in the hypertrophied and failing heart.

  1992cited by this paper
• Altered Myocardial Force‐Frequency Relation in Human Heart Failure

  1992cited by this paper
• Alteration of contractile function and excitation-contraction coupling in dilated cardiomyopathy.

  1992cited by this paper
• Expression of A-, B-, and C-type natriuretic peptide genes in failing and developing human ventricles. Correlation with expression of the Ca(2+)-ATPase gene.

  1992cited by this paper
• Modification of subcellular organelles in pressure‐overloaded heart by etomoxir, a carnitine palmitoyltransferase I inhibitor

  1992cited by this paper
• Effect of thyroid hormone on the expression of mRNA encoding sarcoplasmic reticulum proteins.

  1991cited by this paper
• Abnormal intracellular modulation of calcium as a major cause of cardiac contractile dysfunction.

  1991cited by this paper
• Energetics of isometric force development in control and volume-overload human myocardium. Comparison with animal species.

  1991cited by this paper
• Function of the sarcoplasmic reticulum and expression of its Ca2(+)-ATPase gene in pressure overload-induced cardiac hypertrophy in the rat.

  1990cited by this paper
• Altered sarcoplasmic reticulum Ca2(+)-ATPase gene expression in the human ventricle during end-stage heart failure.

  1990cited by this paper
• Glucose and palmitate oxidation in isolated working rat hearts reperfused after a period of transient global ischemia.

  1990cited by this paper
• Role of intracellular calcium handling in force-interval relationships of human ventricular myocardium.

  1990cited by this paper
• Regulation of ketogenesis and the renaissance of carnitine palmitoyltransferase.

  1989cited by this paper
• Protection of Human Left Ventricular Myocardium From Cutting Injury With 2,3 -Butanedione Monoxime

  1989cited by this paper
• Regulation of myocardial Ca2+-ATPase and phospholamban mRNA expression in response to pressure overload and thyroid hormone.

  1989cited by this paper
• Reversal of the force-frequency relationship in working myocardium from patients with end-stage heart failure

  1988cited by this paper
• Force transient time course in heart muscle with high and low V1 to V3 myosin isoenzyme ratio.

  1988cited by this paper
• Thyroid hormone markedly increases the mRNA coding for sarcoplasmic reticulum Ca2+-ATPase in the rat heart.

  1988cited by this paper
• Myosin heavy chain messenger RNA and protein isoform transitions during cardiac hypertrophy. Interaction between hemodynamic and thyroid hormone-induced signals.

  1987cited by this paper
• Calcium uptake by cardiac sarcoplasmic reticulum in human dilated cardiomyopathy.

  1987cited by this paper
• Abnormal intracellular calcium handling in myocardium from patients with end-stage heart failure.

  1987cited by this paper
• Diabetes mellitus and hypothyroidism induce changes in myosin isoenzyme distribution in the rat heart--do alterations in fuel flux mediate these changes?

  1986cited by this paper
• Decrease of fatty acid oxidation, ketogenesis and gluconeogenesis in isolated perfused rat liver by phenylalkyl oxirane carboxylate (B 807-27) due to inhibition of CPT I (EC 2.3.1.21).

  1985cited by this paper
• The Economy of Isometric Force Development, Myosin Isoenzyme Pattern and Myofibrillar ATPase Activity in Normal and Hypothyroid Rat Myocardium

  1985cited by this paper
• Energetic changes of myocardium as an adaptation to chronic hemodynamic overload and thyroid gland activity

  1985cited by this paper
• Inhibition of hepatic and skeletal muscle carnitine palmitoyltransferase I by 2[5(4-chlorophenyl)pentyl]-oxirane-2-carbonyl-CoA

  1984cited by this paper
• The effects of 2[5(4-chlorophenyl)pentyl]oxirane-2-carbonyl-Co-A on mitochondrial oxidations.

  1984cited by this paper
• Mechanics and energetics in cardiac hypertrophy as related to the iso enzyme pattern of myosin

  1983cited by this paper
• Increased Myothermal Economy of Isometric Force Generation in Compensated Cardiac Hypertrophy Induced by Pulmonary Artery Constriction in the Rabbit: A Characterization of Heat Liberation in Normal and Hypertrophied Right Ventricular Papillary Muscles

  1982cited by this paper
• Electrophoretic analysis of multiple forms of rat cardiac myosin: effects of hypophysectomy and thyroxine replacement.

  1978cited by this paper

• Targeting mitochondrial homeostasis as a cancer treatment strategy: current status and future prospects

  2026cites this paper
• Unrestrained fatty acid oxidation triggers heart failure in mice via cardiolipin loss and mitochondrial dysfunction

  2026cites this paper
• CD36 knockdown attenuates pressure overload-induced cardiac injury by preventing lipotoxicity and improving myocardial energy metabolism

  2025cites this paper
• Energy metabolism in health and diseases

  2025cites this paper
• Molecular mechanisms for pathophysiology and therapy of cardiac dysfunction in heart failure

  2025cites this paper
• Cardiac intermediary metabolism in heart failure: substrate use, signalling roles and therapeutic targets

  2025cites this paper
• AAV-mediated overexpression of CPT1B protects from cardiac hypertrophy and heart failure in a murine pressure overload model

  2025cites this paper
• Modulation of cardiac fatty acid or glucose oxidation to treat heart failure in preclinical models: a systematic review and meta-analysis

  2025cites this paper
• LCAT Deficiency Promotes Hepatocellular Carcinoma Progression and Lenvatinib Resistance by Promoting Triglyceride Catabolism and Fatty Acid Oxidation.

  2025cites this paper
• Imaging of metabolic dysfunction in genetic cardiomyopathies

  2025cites this paper
• DHA, a potentially therapeutic lipid for myocardial infarction

  2025cites this paper
• Accumulation of newly synthesized docosahexaenoic acid plays an essential role in heart regeneration

  2025cites this paper
• Lipolysis-stimulated lipoprotein receptor promote lipid uptake and fatty acid oxidation in gastric cancer

  2024cites this paper
• 2-Methoxyestradiol ameliorates doxorubicin-induced cardiotoxicity by regulating the expression of GLUT4 and CPT-1B in female rats

  2024cites this paper
• Advances in myocardial energy metabolism: metabolic remodelling in heart failure and beyond

  2024cites this paper
• Metabolic regulation in normal and leukemic stem cells.

  2024cites this paper
• Inhibition of choline metabolism in an angioimmunoblastic T-cell lymphoma preclinical model reveals a new metabolic vulnerability as possible target for treatment

  2024cites this paper
• Reversing metabolic reprogramming by CPT1 inhibition with etomoxir promotes cardiomyocyte proliferation and heart regeneration via DUSP1 ADP-ribosylation-mediated p38 MAPK phosphorylation

  2024cites this paper
• Shared molecular, cellular, and environmental hallmarks in cardiovascular disease and cancer: Any place for drug repurposing?

  2024cites this paper
• Myocardial Metabolism in Heart Failure with Preserved Ejection Fraction

  2024cites this paper
• Metabolic mechanisms in physiological and pathological cardiac hypertrophy: new paradigms and challenges

  2023cites this paper
• Retained Metabolic Flexibility of the Failing Human Heart

  2023cites this paper
• From Energy Metabolic Change to Precision Therapy: a Holistic View of Energy Metabolism in Heart Failure

  2023cites this paper
• Advances in Metabolic Remodeling and Intervention Strategies in Heart Failure

  2023cites this paper
• Improving mitochondrial function in preclinical models of heart failure: therapeutic targets for future clinical therapies?

  2023cites this paper
• Targeting c-Jun inhibits fatty acid oxidation to overcome tamoxifen resistance in estrogen receptor-positive breast cancer

  2023cites this paper
• Novelties in the pharmacological approaches for chronic heart failure: new drugs and cardiovascular targets

  2023cites this paper
• Effects of melatonin on cardiac metabolic reprogramming in doxorubicin‐induced heart failure rats: A metabolomics study for potential therapeutic targets

  2023cites this paper
• Metabolic Approaches for the Treatment of Dilated Cardiomyopathy

  2023cites this paper
• Stimulating cardiac glucose oxidation lessens the severity of heart failure in aged female mice

  2023cites this paper
• Current status and emerging trends of cardiac metabolism from the past 20 years: A bibliometric study

  2023cites this paper
• Cardiac Metabolism, Reprogramming, and Diseases

  2023cites this paper
• Integrated Control of Fatty Acid Metabolism in Heart Failure

  2023cites this paper
• PGRMC1 Ablation Protects from Energy-Starved Heart Failure by Promoting Fatty Acid/Pyruvate Oxidation

  2023cites this paper
• Metabolic adaptations in pressure overload hypertrophic heart

  2023cites this paper
• Restoration of CPT1A-mediated fatty acid oxidation in mesothelial cells protects against peritoneal fibrosis

  2023cites this paper
• Mitochondria as Therapeutic Targets in Heart Failure

  2022cites this paper
• Targeting fatty acid β-oxidation impairs monocyte differentiation and prolongs heart allograft survival

  2022cites this paper
• Identification of hub genes and transcription factor regulatory network for heart failure using RNA-seq data and robust rank aggregation analysis

  2022cites this paper
• Animal Models of Dysregulated Cardiac Metabolism

  2022cites this paper
• Targeting Myocardial Substrate Metabolism in the Failing Heart: Ready for Prime Time?

  2022cites this paper
• Progress of potential drugs targeted in lipid metabolism research

  2022cites this paper
• Design and rationale of the EMPA‐VISION trial: investigating the metabolic effects of empagliflozin in patients with heart failure

  2021cites this paper
• The promise and problems of metabolic-based therapies for heart failure.

  2021cites this paper
• Epigenetic Regulation of Adipogenesis in Development of Metabolic Syndrome

  2021cites this paper
• Cardiac Energy Metabolism in Heart Failure

  2021cites this paper
• Design and rationale of the EMPA-VISION trial: investigating the metabolic effects of empagli fl ozin in patients with heart failure

  2021cites this paper
• Phosphorylation-Dependent Interactome of Ryanodine Receptor Type 2 in the Heart

  2021cites this paper
• Targeting Adrenergic Receptors in Metabolic Therapies for Heart Failure

  2021cites this paper
• Mitochondrial Dysfunction and Mitochondrial Therapies in Heart Failure.

  2021cites this paper
• Cardiometabolism as an Interlocking Puzzle between the Healthy and Diseased Heart: New Frontiers in Therapeutic Applications

  2021cites this paper
• Relief of Ischemia in Ischemic Cardiomyopathy

  2021cites this paper
• Ketone Therapy for Heart Failure: Current Evidence for Clinical Use.

  2021cites this paper
• Alterations in Cardiac Metabolism in Heart Failure

  2020cites this paper
• α1-Adrenergic receptors increase glucose oxidation under normal and ischemic conditions in adult mouse cardiomyocytes

  2020cites this paper
• Long-Chain Acylcarnitines and Cardiac Excitation-Contraction Coupling: Links to Arrhythmias

  2020cites this paper
• Changes in Myocardial Metabolism Preceding Sudden Cardiac Death

  2020cites this paper
• Mitochondria in cancer

  2020cites this paper
• Cardiac foetal reprogramming: a tool to exploit novel treatment targets for the failing heart

  2020cites this paper
• Metabolic Profiling of Aortic Stenosis and Hypertrophic Cardiomyopathy Identifies Mechanistic Contrasts in Substrate Utilisation

  2019cites this paper
• Role of Targeted Therapy in Dilated Cardiomyopathy: The Challenging Road Toward a Personalized Approach

  2019cites this paper
• Altered mitochondrial metabolism in the insulin‐resistant heart

  2019cites this paper
• miR-21-5p regulates mitochondrial respiration and lipid content in H9C2 cells.

  2019cites this paper
• Glucose Metabolism in Cardiac Hypertrophy and Heart Failure

  2019cites this paper
• Human Contraceptives: Current Status, Sperm Antigen Inhibitors and an Insight into PCSK4

  2019cites this paper
• Novel Concepts in Cardiac Energy Metabolism: From Biology to Disease

  2019cites this paper
• Targeting CPT1A-mediated fatty acid oxidation sensitizes nasopharyngeal carcinoma to radiation therapy

  2018cites this paper
• AMPK: a therapeutic target of heart failure—not only metabolism regulation

  2018cites this paper
• Loss of Metabolic Flexibility in the Failing Heart

  2018cites this paper
• DUSP6 mediates T cell receptor-engaged glycolysis and restrains TFH cell differentiation

  2018influential citation
• Targeting mitochondria for cardiovascular disorders: therapeutic potential and obstacles

  2018cites this paper
• Metabolic Modulators in Heart Disease: Past, Present, and Future.

  2017cites this paper
• Dioxygen and Metabolism; Dangerous Liaisons in Cardiac Function and Disease

  2017cites this paper
• Cardiac metabolism — A promising therapeutic target for heart failure

  2017cites this paper
• The 'Goldilocks zone' of fatty acid metabolism; to ensure that the relationship with cardiac function is just right.

  2017cites this paper
• Peroxisome proliferator-activated receptors as therapeutic targets for heart failure.

  2017cites this paper
• Pharmacological inhibition of carnitine palmitoyltransferase 1 restores mitochondrial oxidative phosphorylation in human trifunctional protein deficient fibroblasts.

  2017cites this paper
• Mitochondrial Function in Non-ischemic Heart Failure.

  2017cites this paper
• Inhibition of sarcolemmal FAT/CD36 by sulfo-N-succinimidyl oleate rapidly corrects metabolism and restores function in the diabetic heart following hypoxia/reoxygenation

  2017cites this paper
• Gr upSM Targeting Lipid Metabolism in Cancer

  2017cites this paper
• Advantages and Limitations of Current Biomarker Research: From Experimental Research to Clinical Application.

  2017cites this paper
• Cardiac Metabolism – The Link to Clinical Practice

  2016cites this paper
• Cardiac Metabolism and Energetic Control

  2016cites this paper
• Mitochondrial Function, Biology, and Role in Disease: A Scientific Statement From the American Heart Association.

  2016cites this paper
• Energy production in the reperfused ischemic heart

  2016cites this paper
• Rationale and benefits of trimetazidine by acting on cardiac metabolism in heart failure.

  2016cites this paper
• Present and future pharmacotherapeutic agents in heart failure: an evolving paradigm

  2016cites this paper
• Review of novel therapeutic targets for improving heart failure treatment based on experimental and clinical studies

  2016cites this paper
• Congenital Aortic Stenosis in a Fetus: A Case Report and Review of Syndromic Associations

  2016cites this paper
• Harnessing Cardiac Energetics in the Treatment of Heart Failure

  2016cites this paper
• The Role of Ivabradine and Trimetazidine in the New ESC HF Guidelines.

  2016cites this paper
• Aberrant Lipid Metabolism Promotes Prostate Cancer: Role in Cell Survival under Hypoxia and Extracellular Vesicles Biogenesis

  2016cites this paper
• Metabolic support for the heart: complementary therapy for heart failure?

  2016cites this paper
• Cardiac‐specific down‐regulation of carnitine palmitoyltransferase‐1b (CPT‐1b) prevents cardiac remodeling in obese mice

  2016influential citation
• Energetic Metabolic Roles in Pulmonary Arterial Hypertension and Right Ventricular Remodeling.

  2016cites this paper
• Targeting Mitochondrial Dysfunction in Chronic Heart Failure: Current Evidence and Potential Approaches.

  2016cites this paper
• Diabetic glucolipotoxic cardiomyopathy : does it exist in humans ?

  2016cites this paper
• Emerging drugs for the treatment of angina pectoris

  2016cites this paper
• Cardiomyocytes – Active Players in Cardiac Disease

  2016cites this paper
• Myocardial Energy Substrate Metabolism in Heart Failure : from Pathways to Therapeutic Targets.

  2015cites this paper